Prof Heinrich Lokhorst talks to ecancer at EHA 18 about results from a phase I/II study in advanced Multiple Myeloma.

Multiple myeloma is the second most common haematological cancer. It is a cancer of the plasma cells and it accounts for approx. 1% of all cancers. At present, no cure is available. The 5-year relative survival rate for multiple myeloma is around 40% so there is a strong need for new treatment modalities to improve the survival.

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

ecancer's filming at EHA has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.